 Aldeyra Therapeutics Incs NASDAQ: ALDX Phase 3 TRANQUILITY-2 trial of reproxalap for dry eye disease has achieved the primary endpoint. Reproxalap was statistically superior to the vehicle for each of the two prespecified primary endpoints, Schirmer test and 10 mm Schirmer. 